A major milestone in respiratory medicine arrived in April 2026 when AstraZeneca announced that Breztri Aerosphere received U.S. Food and Drug Administration approval for the maintenance treatment of asthma in adults and children aged 12 years and older. This makes Breztri the first and only approved triple-combination inhaler for asthma in a single device in the United States.
The decision could change treatment pathways for millions of people whose asthma remains uncontrolled despite standard dual therapy. For patients who still experience wheezing, flare-ups, shortness of breath, and daily limitations, this new option may offer better symptom control and improved lung function.
Breztri Aerosphere is an inhaled prescription medicine that combines three different therapies into one inhaler:
This triple-action approach targets multiple causes of asthma symptoms at the same time. Instead of relying on separate inhalers or escalating therapies, eligible patients may now use one maintenance inhaler containing all three components.
Asthma affects around 27 million people in the United States and hundreds of millions worldwide. Despite the availability of current treatments, many patients remain uncontrolled on standard inhaled corticosteroid and LABA combinations.
Uncontrolled asthma can lead to:
The approval of Breztri gives physicians a new step-up treatment option for patients who need more than dual therapy.
The FDA approval was supported by data from the KALOS and LOGOS Phase III clinical trials. These were large, randomized, double-blind studies involving approximately 4,300 patients with inadequately controlled asthma.
According to AstraZeneca, Breztri showed:
The results were published in The Lancet Respiratory Medicine in February 2026.
Breztri may be considered for:
Doctors will still determine whether triple therapy is appropriate based on asthma severity, prior medication response, and overall health history.
Although Breztri can improve long-term asthma control, it is not used to relieve sudden breathing problems.
Patients should continue carrying a rescue inhaler such as albuterol or another prescribed fast-acting bronchodilator for acute symptoms.
Breztri was already approved in the U.S. in 2020 for chronic obstructive pulmonary disease (COPD). The product has since gained broad global use and was reportedly prescribed to more than 6.8 million patients worldwide in 2025.
This new asthma indication expands AstraZeneca’s role in respiratory medicine and reflects growing interest in combination inhalers that simplify treatment while improving outcomes.
The approval of Breztri signals a broader shift toward more personalized asthma treatment. Rather than using the same stepwise approach for every patient, doctors increasingly match therapy intensity to symptom burden and risk.
Single-inhaler triple therapy may help reduce:
If real-world outcomes mirror clinical trial success, Breztri could become an important option for patients struggling with moderate to severe asthma.
For many people, asthma remains a daily challenge despite modern treatments. The FDA approval of Breztri Aerosphere for patients aged 12 and older introduces a new option that combines three proven medication classes into one inhaler.
While not every patient will need triple therapy, those who continue to experience symptoms on standard treatment may now have access to a more comprehensive maintenance approach.
Anyone interested in Breztri should speak with a licensed healthcare professional to determine whether it fits their treatment plan.
AstraZeneca announcement.
This article is for educational and informational purposes only and is not medical advice. It does not replace consultation with a physician, pharmacist, or qualified healthcare provider. Always seek professional guidance before starting, stopping, or changing any medication or asthma treatment.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.